Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ENTB is a subsidiary company of BMSN.
It's just an attempt to spoof share holders unfamiliar with biotech lingo to scare them out of their shares. That's part of his tactics of posting partial info or making his personal interpretation of what the paragraph(s) say verses what they really mean.
They won't due to privacy reasons.
Yes it is. That's why I have mobile L2 also!
$BMSN on the run....$0.0126 current
True that!
Sometimes MMs holding share price down is a good thing. Helps keep it real. Other times it isn't a good thing. I think it's a good thing here so far.
We are still waiting for IND news any day! It ain't over til the fat lady sings!
NITE has been one of the main MMs holding this down for weeks.
iHub L2
False information
I interpret that as they announced today they filed...
Not that they announced they filed it today.
Actually, the 5 Feb PR simply states it was filed. Does not specify "today" or any other date. Simply it was filed.
My concern is ppl are specifying a specific date they think is the 30 day mark as a matter of fact. We do not know what specific date is the 30 days based upon information provided by the company's PR. This only opens up for ppl to start screaming scam when dates ppl post on the board come and go with no news. Other ppl reading the board my believe the dates being thrown out there are a matter of fact.
That's my point.
Ensure you read through stervc's DD post.
A lot of good information compiled over the last few weeks for all to read. Some of the info is speculation by stervc and others. Most is verifiable information with links provided (something the bashers can't or won't do)!
Know what you own!!!
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=85227700
It's just the calm before the storm. Typical, just prior to the pending FDA news release date on most biotechs.
Don't listen to the bashers, they are only hoping to get in at a lower price or are shorting the stock. They try to put fear into traders, but on BMSN, none of them have yet to provide links to any source to back up their negative claims against the company or people involved with the company. This is gonna fly when positive news of IND approval is released. And again once the Orphan Drug Status application moves forward for FDA reveiw/possible approval. Hold on to your shares or jump in now, if not already in.
The guidance provided on the FDA website only states 30 days. It does not specify if only business or calendar days.
However, the 5 Feb PR doesn't state what date the IND application was received by the FDA. The received/accepted date by the FDA is the key date. The 5 Feb date of the PR is only a date we can use as an approximate date. We do not know if they put the PR out after they submitted and had delivery comfirmation the FDA received the application, or if the put the PR out right after they stuck the application in the mail.
Not during that period according to otcmarkets.com
http://www.otcmarkets.com/stock/CTIC/company-info
This is an example of what could happen (not saying it will; but could!!)...This is an example of a company that was in bankruptcy status at the time FDA approved...
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=85151212
30 days for IND. 60 days for orphan drug after IND approval.
The FDA guideline only specifies 30 days. Does not state business days! Also, 5 Feb is the date of the PR. We do not know the actual date the FDA received the application...that is the key date. We can only use the 5th as an approximate start date.
No, most MMs pull their positions off L2 after hours. Every trading morning they reload them back to L2, some as late as a few minutes before opening bell. Only a few MMs leave their positions sitting on L2 after hours.
ETRF is E-Trade retail
Sweet! We'll be green tomorrow!! Thanks Paris
This is not to make any prediction of what BMSN's potential gain probability will be. It is simply to demonstrate how explosive the boitech stocks can get upon FDA approvals. This also may not be typical of all biotechs!
www.biomedreports.com/2009111818487/ready-to-run-power3-medical-products-otcpwrm.html
Ready to Run: Power3 Medical Products (OTC: PWRM)
By M.E.Garza
Wednesday, 18 November 2009 03:00
No conversation about blood diagnostic stocks is complete without first discussing what many biotech investors call the "Vermillion Dollar baby." So before we talk about PWRM, let's put things into perspective and start there.
On September 16 2009, Vermillion, Inc. (OTC:VRMLQ), the anguished little company seeking Chapter 11 bankruptcy protection, received clearance for it's ovarian cancer diagnostic test from the US Food and Drug Administration. That morning, shares in the company went from pennies to a dollar on the news.
Calls and angry e-mails began flooding the offices of BioMedReports in Los Angeles. Subscriber after upset subscriber asking:
"Why wasn't VRMLQ on your FDA Calendar as one of the companies to invest in?" "How could you guys miss this?"
We had omitted the company because we would never knowingly advise anyone to invest in a company headed for bankruptcy and that's clearly what Vermillion was prior to that fateful morning. They had been struggling for three years to stay alive and the decision from the FDA was "a Hail Mary pass that brought Vermillion back into the game."
What happened next was even more surprising.
Even though the company still faces huge financial hurdles, it's low float and excitement about its OVA1 cancer diagnostic test sent shares from that single dollar to over $21 as of yesterday. (((My personal NOTE: That would have been 17 Nov 09; 2 months after FDA approval)))
If you were one of the readers who complained that you missed that trade at $1, I can only imagine how you're feeling today.
The same fortune hunters who threw caution to the wind and gambled big on VRMLQ are now keeping their fingers crossed that Quest Diagnostics (NYSE:DGX) will dip into its war chest to buy Vermillion. After all, Vermillion is the same company Quest gave plentiful collaboration and boat loads of loan money to in order to keep the company afloat and focused on developing that OVA1 test- which Quests controls all rights to now, anyway.
That test is based on "biomarkers" and is the first FDA-cleared test that can indicate the likelihood of ovarian cancer with high sensitivity before a biopsy or exploratory surgery, but interestingly, the FDA has said the test is only intended for women ages 18 and older who are already selected for surgery and it is not intended for use as a screening device for ovarian cancer or as a definitive diagnosis for the disease. The potential patient population for that test according to most estimates and published reports, ranges between 1 million and 5 million patients annually.
That brings us to what could easily become the next "Vermillion Dollar Baby."
Our only hope those of you who complained that we missed VRMLQ are paying close attention now.
Power3 Medical Products (OTC:PWRM) is a company that is developing several tests for early detection, monitoring and targeting of diseases in much, much bigger potential markets like Alzheimer's, Pakinsons and breast cancer.
Their NuroPro® product is a series of three separate and distinct blood serum tests designed to diagnose: Alzheimer’s, Parkinson’s or Lou Gehrig’s disease (ALS) in individuals. The biomarkers in the panel have been selected for their ability to discriminate diseased from non-diseased patients. Power3’s statistical model evaluates the quantitative information of the protein biomarkers and automatically assigns a probability score. The probability score indicates to the physician that the patient has a Neurological disease or is disease-free.
Because of the downturn in the economy, like most companies, Power3 Medical was forced to reduce the size of the company for space and personnel, but they were smart enough to to shift it's pipeline positioning and put most of their resources into that test- which in the U.S. alone presents the company and it's partners a screening opportunity worth $31.2 billion and there are no other current blood based test available for early stage diagnosis or monitoring of therapies in development. (Source: NIMH, Alzheimer’s Association)
Power3's BC-SeraPro™ blood serum test not only shows great promise in diagnosing breast cancer in individuals, but perhaps more importantly, it brings a not too distant future in which women will no longer have to experience uncomfortable mammograms, whose results very often give false negatives/positives for breast cancer. The test is also important because, today, by the time breast cancer is detected, it has already been present for six years.
Genomic Health, Inc. (NASDAQ:GHDX) has a diagnostic test (Oncotype DX) which is used for breast cancer patients. But it is only used to predict the likelihood of cancer recurrence and the likelihood of chemotherapy. That genomic-based clinical diagnostic tests basically allows physicians and patients to make individualized treatment decisions. That company's shares trade in the $20 range.
Like most of our recent recommendations, this investment/trade idea also comes with an important pending news catalyst.
With years of development of their technology and intellectual property, and with commercialization in sight, Power3 is at a critical point in the company’s growth. Company CEO, Helen Park told BioMedReports on Tuesday afternoon:
"Power3 Medical Products has recently completed the Phase I Clinical Trials for Alzheimer's and Parkinson's diseases blood diagnostic tests with better than expected results and launched the Phase II clinical trials for both of these diseases. Our Chief Scientific Officer, Dr. Ira Goldknopf, is reporting new information on these results at the BIT meeting in China this week."
Ms. Park is referring to an invited Keynote address and chair a session on “Biomarkers and Diagnostics in Personalized Medicine,” at the BIT Life Sciences 2nd International Congress and Expo of Molecular Diagnostics in Beijing, China, which kicks off Thursday November 19 and runs through Sunday, November 21, 2009. The Theme of the meeting is “New Leadership of Personalized Medicine.”
In his scheduled Keynote address, entitled “Principles of Omic Medicine Applied to Differential Diagnosis - Breast Cancer and Neurodegenerative Diseases,” Dr. Goldknopf will discuss the “necessary fundamental principles” that BC-SeraPro™ and NuroPro® exemplify which enable the company’s biomarkers and tests to “more effectively address the unmet clinical needs that challenge us today.” He will describe the company’s unique position and ability to use biomarkers for testing in personalized medicine and the various facets that are required for discovery, validation and to commercialize a group of biomarkers. If the news and results he reveals are as significant and promising as thought, we believe that this company could see a significant run up in it's share price before, during and after his presentation.
“For physicians to order a test for a patient, they first need to believe in it. That takes major international scientific acceptance and publication in peer-reviewed journals. This meeting is an excellent opportunity to showcase worldwide the strides we have made through refinements in our biomarkers and blood test for early stage detection of breast cancer (BC-SeraPro, GLOBE NEWSWIRE Aug. 20, 2009),” said Dr. Goldknopf in a September press release. “Earlier presentations on Alzheimer’s and Parkinson’s disease biomarkers and tests were given at the annual meetings of the American Academy of Neurology in Seattle and the International Congress of Alzheimer’s Disease in Vienna. We recently published the Parkinson’s disease biomarkers and test results in Biochemical and Biophysical Research Communications (Reuters Sept. 2, 2009), and more publications are in the works.”
“We are extremely proud and excited about the recognition of Dr. Goldknopf and Power3 by the opportunity to chair this session and present at this international meeting,” said Ms. Helen Park, Power3’s CEO. “Dr. Goldknopf is the Keynote speaker and will feature new progress in clinical validation of the company’s biomarkers and blood test for early stage diagnosis of breast cancer leading to commercialization.”
Here's what we like: The company has tests and biomarkers that are in the process of validation in Phase II clinical trials. This is not an overnight sensation. PWRM has improved the technology for 10 years using proprietary procedures. And their management team and partners have experience in the commercialization of diagnostic tests.
So while we will undoubtedly keep readers posted as to new pending developments, we must also call the current stock action to your attention.
Yesterday, our premium subscribers were told that this special report on the company was going to be released today. While no other news or information was shared at the time, a link to the company's website was provided along with a brief description about the company's technologies.
Immediately, investors reacted by taking shares from $.08 to $.13 on a volume of over 21 million shares. The stock experienced a near 70% bump in price with very little sell-off. While this is certainly impressive, we are of the opinion that the is only the begining of a run that will send shares up considerably in the coming days and weeks.
The medical community's interest in these new tests, huge market potential, pending positive news, partnerships and technical analysis here look very solid and the stock will open on Wednesday roughly three cents away from potential break-out over a previous level of resistance and previous high. Furthermore, unlike other stocks which we feel are bought on rumor and sold on news, we feel investors will likely hold through the upcoming presentation by Dr. Goldknopf for further gains. Especially as news about this company and their progress on clinical trials spreads.
I just fear everyone is expecting news on or before a specific date based on 5 Feb and if that news doesn't come on or before that date, everyone starts screaming scam! People have to remember to be flexible with the date, as we do not know the exact date the FDA received the package!! But to remember, that date can be any moment, so don't give up your shares to fear if MMs play tank games between now and then!!
Exactly, that's why 5 Feb is just a date of reference to estimate the 30-day timeline. Not to determine a firm date!
7 Mar is not a firm date!!
Actual day of accepted with no news is Thursday March 7. That is the end of the 30 days. Just a few more hours of waiting. No big deal.
pumpanddumps.com is a known short trader! Kinda ironic to create a website that list most stocks as a PnD when you are shorting on the stocks listed on your website warning everyone about!! Hmmm
LOL...You know it!! I think we will all be doing the Harlem Shake!!
BioTech News Stock Reveiw is not a credible news information site! This is the garbage they posted this morning that started the hype this morning:
http://biotechnewsstockreview.blogspot.com/2013_02_01_archive.html
This is their disclaimer (bottom of same page):
DISCLAIMER:
This blog is for fictional and entertainment purposes only! Best Penny Stocks Review and it's publisher, do not accept payment to feature or recommend any stock. Nobody knows about our stock picks before they are published live on the Blog. We are not affiliated with any executives, owners, brokers, promoters or trading groups.The publisher is not a registered investment adviser. Readers and subscribers should not view information found within this domain as offering personalized, legal, tax, accounting, stock or investment-related advice. Viewpoints, information, entertainment and fictional posts presented within this blog are our own, accuracy is not guaranteed. Any hyper-links listed on this site that link back to any other web sites are not to be construed as an endorsement by us of that particular site, its products, or its contents. Hyper-links to other sites should be visited at your own risk. All materials presented on this web site are not to be regarded as investment advice and are only offered for fictional and entertainment purposes. Before making a purchase or sale of any securities featured on this site, we strongly recommend consultation with a registered securities representative. This blog is not to be construed as a solicitation to buy or sell securities. Any stock pick recommendation or companies selected or presented involve a high degree of investment risk and volatility. All investors are cautioned that they may lose all or a portion of their investment if they decide to make a purchase in any stock picks presented within this web site. Penny stocks, small cap stocks, mid cap stocks should be viewed as very high-risk speculations. It should be understood that there is no guarantee that past performance will be indicative of future results. The accuracy, information or completeness of the picks posted on this blog is for fictional and entertainment purposes only! We do not guarantee that any or all of our stock picks will ever increase in value (share price) at any particular time after the pick goes live on the blog since all stocks can decrease in value at any time. It is your decision alone to buy or sell any stock presented on this site. All characters ever mentioned and presented by the publisher in this blog are fictional characters and all posts in the blog should be construed as being for fictional and entertainment purposes only! Safe Harbor Disclosure: The information and services contained within this site may include or incorporate by reference “forward looking statements” including certain information with respect to plans and strategies of featured companies. For this purpose, any statements on the site or incorporated by reference that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting or forgoing the words “should”, “could”, “may” “believe”, “anticipate”, “plan”, "ventures", “expect”, “project” and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks, uncertainties, and assumptions about each company, economic and market factors in industries in which the companies do business, among other factors. These statements are in no way guarantees of future performances and actual events, and results may differ materially from those expressed or forecasted by the companies due to many factors. For further information about securities and their regulation, visit the site of the Securities and Exchange Commission (SEC) at www.sec.gov
It doesn't prove BMSN is worthless, it just shows that the Biotech News blog website is not a reliable source of information!!
BMSN will move up when REAL RELIABLE news hits the streets!!
We already had all that hype going on here this morning. All based on a comment put on a rumor mill blog website. A site that has no credible "predictions".
Bruce...I have to admit, I was excited too! But i had to face reality with myself of the source we were seeing this info. i already knew they weren't a reliable source. The website was just created in mid Jan of this year. Even with their own claim on their site stating they are 90% accurate in their predictions. I'm not sure that has been verified!
This isn't moving until REAL verifiable news of IND approval is released. Not over hype over a comment posted on a rumor mill blog website!! As I stated this morning!
Long and strong ENTB! Looking for REAL news!!
This isn't moving until REAL verifiable news of IND approval is released. Not over hype over a comment posted on a rumor mill blog website!! As I stated this morning!
Long and strong BMSN! Looking for REAL news!!
It's too early for L2 to give you a good idea of what the opening bid is gonna be!!!
"They say" Exactly my point! I guess all their predictions on AMB* must have fallen in the 10% of their failed predictions, not to mention some of the other tickers they made predictions on including some of the nonsense predictions they have stated concerning BMSN.
This site has only been in existence since mid Jan 2013.
Unreliable source...here's their disclaimer:
http://www.biotechnewsstockreview.com/disclaimer-and-privacy-policy/
DISCLAIMER
This website is for fictional and entertainment purposes only! Biotech News Stock Review and it’s publisher, do not accept payment to feature or recommend any stock. Nobody knows about our stock picks before they are published live on the website. We are not affiliated with any executives, owners, brokers, promoters or trading groups.The publisher is not a registered investment advisor. Readers and subscribers should not view information found within this domain as offering personalized, legal, tax, accounting, stock or investment-related advice. Viewpoints, information, entertainment and fictional posts presented within this website are our own, accuracy is not guaranteed. Any hyper-links listed on this site that link back to any other websites are not to be construed as an endorsement by us of that particular site, its products, or its contents. Hyper-links to other sites should be visited at your own risk. All materials presented on this website are not to be regarded as investment advice and are only offered for fictional and entertainment purposes. Before making a purchase or sale of any securities featured on this site, we strongly recommend consultation with a registered securities representative. This website is not to be construed as a solicitation to buy or sell securities. Any stock pick recommendation or companies selected or presented involve a high degree of investment risk and volatility. All investors are cautioned that they may lose all or a portion of their investment if they decide to make a purchase in any stock picks presented within this website. Penny stocks, small cap stocks, mid cap stocks should be viewed as very high-risk speculations. It should be understood that there is no guarantee that past performance will be indicative of future results. The accuracy, information or completeness of the picks posted on this website is for fictional and entertainment purposes only! We do not guarantee that any or all of our stock picks will ever increase in value (share price) at any particular time after the pick goes live on the website since all stocks can decrease in value at any time. It is your decision alone to buy or sell any stock presented on this site. All characters ever mentioned and presented by the publisher in this website are fictional characters and all posts in the website should be construed as being for fictional and entertainment purposes only! Safe Harbor Disclosure: The information and services contained within this site may include or incorporate by reference “forward looking statements” including certain information with respect to plans and strategies of featured companies. For this purpose, any statements on the site or incorporated by reference that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting or forgoing the words “should”, “could”, “may” “believe”, “anticipate”, “plan”, “ventures”, “expect”, “project” and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks, uncertainties, and assumptions about each company, economic and market factors in industries in which the companies do business, among other factors. These statements are in no way guarantees of future performances and actual events, and results may differ materially from those expressed or forecasted by the companies due to many factors. For further information about securities and their regulation, visit the site of the Securities and Exchange Commission (SEC) at www.sec.gov